Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CNOOC
00883
5
SHANGHAI PECHEM
00338
CN Stock MarketDetailed Quotes
Harbin Medisan Pharmaceutical (002900)
- 11.49
- +0.59+5.41%
Market Closed Apr 28 15:00 CST
3.63BMarket Cap-11.43P/E (TTM)
11.73High10.91Low147.85KlotVolume10.95Open10.90Prev Close170.31MTurnover9.18%Turnover RatioLossP/E (Static)316.35MShares17.8652wk High2.06P/B1.85BFloat Cap10.4852wk Low11.99Limit Up161.12MShs Float36.10Historical High9.81Limit Down7.52%Range %6.27Historical Low0.20Dividend TTM11.52Avg Price60.42KlotAsk1.74%Div Yield TTM100Lot Size83.10KlotBid
Harbin Medisan Pharmaceutical (002900) Income Statement
All
YOY
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 11.61%228.84M | -30.29%789.42M | -30.75%580.65M | -21.08%413.12M | -16.93%205.03M | -4.58%1.13B | -9.10%838.53M | -17.86%523.44M | -27.86%246.82M | 15.40%1.19B |
| Operating revenue | 11.61%228.84M | -30.29%789.42M | -30.75%580.65M | -21.08%413.12M | -16.93%205.03M | -4.58%1.13B | -9.10%838.53M | -17.86%523.44M | -27.86%246.82M | 15.40%1.19B |
| Other operating revenue | ---- | 33.76%82.45M | ---- | 25.88%42.4M | ---- | 80.82%61.64M | ---- | 91.66%33.68M | ---- | 68.22%34.09M |
| Total operating cost | 7.25%260.08M | -0.23%1.1B | -6.65%772.65M | -0.94%514.47M | -1.81%242.5M | -7.73%1.11B | -9.96%827.69M | -17.26%519.35M | -24.72%246.97M | 13.15%1.2B |
| Operating cost | 16.88%135.29M | -11.03%491.61M | -17.75%337.23M | -1.25%237.29M | 9.22%115.75M | 15.99%552.57M | 18.09%410.02M | 7.99%240.28M | -16.82%105.98M | 30.31%476.38M |
| Operating tax surcharges | 15.69%3.53M | 0.50%11.95M | 3.56%9.21M | 2.22%5.99M | 0.75%3.06M | -19.18%11.89M | -24.29%8.89M | -29.60%5.86M | -30.70%3.03M | -6.05%14.71M |
| Operating expense | 16.80%61.62M | 6.90%280.3M | -2.79%201.24M | -13.20%128.86M | -34.67%52.76M | -37.84%262.2M | -42.80%207.01M | -44.31%148.45M | -44.01%80.76M | -7.07%421.8M |
| Administration expense | -15.96%40.15M | 22.25%207.64M | 17.50%148.76M | 18.89%96.25M | 22.00%47.78M | -3.69%169.85M | 1.47%126.61M | -1.51%80.95M | 14.61%39.16M | 25.35%176.36M |
| Financial expense | 33.71%5.85M | 387.25%18.25M | 3,555.24%12.78M | 286.87%8.15M | 165.74%4.38M | 194.18%3.75M | 91.01%-369.95K | -15.26%-4.36M | -182.51%-6.66M | 36.81%-3.98M |
| -Interest expense (Financial expense) | -1.10%7.44M | -15.33%26.23M | -14.00%19.51M | -10.11%13.53M | 8.37%7.53M | 35.34%30.98M | 33.52%22.69M | 34.20%15.05M | 22.63%6.95M | 1.29%22.89M |
| -Interest Income (Financial expense) | 63.88%-1.19M | 66.93%-7.62M | 65.65%-6.55M | 65.57%-5.18M | 64.35%-3.3M | 14.41%-23.04M | 8.13%-19.07M | -5.41%-15.05M | -24.56%-9.25M | 4.86%-26.91M |
| Research and development | -27.47%13.62M | -11.46%93.16M | -16.02%63.44M | -21.22%37.94M | -23.94%18.78M | -6.73%105.22M | -2.85%75.54M | -7.15%48.16M | 22.06%24.69M | 26.37%112.81M |
| Credit Impairment Loss | -787.78%-1.23M | 332.04%2.96M | 783.77%1.75M | 433.43%369.05K | 1,359.23%178.43K | -145.80%-1.27M | -76.61%198.51K | -135.68%-110.68K | -108.68%-14.17K | 490.27%2.78M |
| Asset Impairment Loss | 319.85%7.17M | -4,814.99%-64.29M | -4,378.31%-53.96M | -890.06%-11.04M | -924.93%-3.26M | -258.34%-1.31M | -217.49%-1.2M | -3.47%-1.12M | -113.74%-318.31K | -84.22%826.15K |
| Other net revenue | 969.99%24.27M | -190.46%-31.66M | -214.48%-34.17M | -117.58%-3.26M | -88.10%2.27M | -61.24%35M | -49.85%29.85M | -60.49%18.54M | -34.74%19.06M | 27.16%90.31M |
| Fair value change income | 0.55%-5M | 22.72%-11.31M | -31.20%-9.77M | -66.90%-11.78M | -236.44%-5.03M | -209.46%-14.64M | -174.21%-7.45M | -156.11%-7.06M | -48.43%3.68M | -3.63%13.37M |
| Invest income | 50.42%8.11M | -33.59%21.53M | -34.75%16.63M | -29.65%11.64M | -32.71%5.39M | -25.69%32.42M | -25.05%25.49M | -32.84%16.55M | -25.78%8.02M | -5.07%43.62M |
| -Including: Investment income associates | 87.73%7.72M | -34.56%19.47M | -35.91%14.62M | -31.22%10.33M | -39.77%4.11M | -16.94%29.74M | -12.98%22.82M | -15.02%15.02M | -16.28%6.83M | -15.47%35.81M |
| Asset deal income | -1,725.15%-358.68K | -367.52%-520.67K | -105.69%-17.68K | -123.58%-48.14K | -111.40%-19.65K | 107.47%194.63K | 111.93%310.68K | 107.93%204.18K | 237.99%172.32K | 80.42%-2.61M |
| Other revenue | 211.05%15.57M | 1.89%19.98M | -10.59%11.18M | -24.55%7.61M | -33.47%5.01M | -39.32%19.61M | -22.85%12.51M | -22.84%10.08M | -33.86%7.52M | 61.79%32.31M |
| Operating profit | 80.20%-6.97M | -656.63%-345.14M | -655.87%-226.18M | -562.11%-104.61M | -286.13%-35.21M | -21.53%62.01M | -35.15%40.69M | -59.91%22.64M | -56.32%18.91M | 94.50%79.02M |
| Add:Non operating Income | -19.91%84.09K | 25.34%631.94K | -11.03%380.29K | -39.30%161.52K | -51.27%105K | -82.60%504.17K | -69.24%427.43K | -80.75%266.09K | 544.71%215.49K | 13.57%2.9M |
| Less:Non operating expense | -97.46%1.28K | 240.75%8.52M | -95.77%58.21K | -96.32%50.38K | 67,778.25%50.24K | 358.81%2.5M | 153.04%1.38M | 184.90%1.37M | --74.01 | -82.48%545.16K |
| Total profit | 80.41%-6.89M | -688.31%-353.03M | -668.32%-225.86M | -585.29%-104.5M | -283.75%-35.15M | -26.26%60.01M | -37.50%39.74M | -62.47%21.53M | -55.85%19.13M | 103.08%81.37M |
| Less:Income tax cost | 115.81%846.69K | -327.94%-11.47M | -741.35%-14.38M | -311.62%-10.22M | -412.12%-5.36M | -55.46%5.03M | -63.40%2.24M | -135.78%-2.48M | -65.95%1.72M | -16.76%11.3M |
| Net profit | 74.04%-7.73M | -721.28%-341.57M | -663.95%-211.48M | -492.53%-94.28M | -271.10%-29.8M | -21.55%54.98M | -34.74%37.5M | -52.37%24.02M | -54.52%17.41M | 164.45%70.08M |
| Net profit from continuing operation | 74.04%-7.73M | -721.28%-341.57M | -663.95%-211.48M | -492.53%-94.28M | -271.10%-29.8M | -21.55%54.98M | -34.74%37.5M | -52.37%24.02M | -54.52%17.41M | 164.45%70.08M |
| Less:Minority Profit | 28.66%-677.95K | 47.50%-1.94M | 14.56%-2.63M | 16.36%-1.89M | 30.90%-950.34K | -3.17%-3.7M | -15.75%-3.08M | -28.09%-2.25M | -58.03%-1.38M | 3.33%-3.58M |
| Net profit of parent company owners | 75.54%-7.06M | -678.82%-339.63M | -614.61%-208.84M | -451.68%-92.39M | -253.52%-28.85M | -20.35%58.68M | -32.50%40.58M | -49.66%26.27M | -52.02%18.79M | 143.86%73.66M |
| Earning per share | ||||||||||
| Basic earning per share | 77.78%-0.02 | -663.16%-1.07 | -607.69%-0.66 | -462.50%-0.29 | -250.00%-0.09 | -20.83%0.19 | -31.58%0.13 | -52.94%0.08 | -53.85%0.06 | 140.00%0.24 |
| Diluted earning per share | 77.78%-0.02 | -663.16%-1.07 | -607.69%-0.66 | -462.50%-0.29 | -250.00%-0.09 | -20.83%0.19 | -31.58%0.13 | -52.94%0.08 | -53.85%0.06 | 140.00%0.24 |
| Other composite income | ||||||||||
| Total composite income | 74.04%-7.73M | -721.28%-341.57M | -663.95%-211.48M | -492.53%-94.28M | -271.10%-29.8M | -21.55%54.98M | -34.74%37.5M | -52.37%24.02M | -54.52%17.41M | 164.45%70.08M |
| Total composite income of parent company owners | 75.54%-7.06M | -678.82%-339.63M | -614.61%-208.84M | -451.68%-92.39M | -253.52%-28.85M | -20.35%58.68M | -32.50%40.58M | -49.66%26.27M | -52.02%18.79M | 143.86%73.66M |
| Total composite income of minority owners | 28.66%-677.95K | 47.50%-1.94M | 14.56%-2.63M | 16.36%-1.89M | 30.90%-950.34K | -3.17%-3.7M | -15.75%-3.08M | -28.09%-2.25M | -58.03%-1.38M | 3.33%-3.58M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Accounting Firm for the Meeting (Special General Partnership) | -- | -- | -- | Zhongxing Cai Guanghua Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhongxing Cai Guanghua Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
In the early hours of the 27th local time, Iran conveyed a three-phase negotiation plan to the US side, indicating that talks could resume i
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm